^
    Back
    Association details:
    Biomarker:FGFR2 amplification
    Cancer:Breast Cancer
    Drug:Truseltiq (infigratinib) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

    Excerpt:
    Incidence rate and category of dose-limiting toxicities will be tabulated for patients included in the dose escalation portion of the study, to establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RPTD) [ Time Frame: 23 months ]
    Trial ID:
    NCT01004224
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

    Excerpt:
    Adult patients were treated with escalating dosages of BGJ398 5 to 150 mg once daily or 50 mg twice daily continuously in 28-day cycles...10 of 32 patients (31%) with breast cancer treated at ≥ 100 mg had a best response of SD. Of 26 patients with breast cancer (FGFR1/2 amplified [n = 25]; FGFR3 mutant [n = 1]) with pre- and post-treatment target lesion measurements, four (15.4%) had reduced tumor burden...
    DOI:
    10.1200/JCO.2016.67.2048
    Trial ID:
    NCT01004224